{
  "id": "DDI-NEPHRO-005",
  "nome": "Anfotericina B + Aminoglicosideos - Nefrotoxicidade Severa",
  "categoria": "Interacao Medicamentosa Nefrotoxica",
  "subcategoria": "Antifungico + Antibiotico",
  "severidade": "CRITICA",
  "evidencia": "NIVEL 1 - Estudos Clinicos, IDSA Guidelines",
  "referencias": [
    "Bates DW et al. Am J Med. 2001;111:177-81",
    "Deray G. Am J Kidney Dis. 2002;40:S11-S17",
    "IDSA Guidelines for Invasive Fungal Infections 2016",
    "Walsh TJ et al. N Engl J Med. 1999;340:764-71"
  ],
  "mecanismo": "Anfotericina B forma poros na membrana celular tubular via ligacao ao ergosterol, causando perda de potassio, magnesio, acidose tubular distal e vasoconstriccao arteriolar aferente. Aminoglicosideos causam necrose tubular proximal. Efeitos sinergicos resultam em IRA severa.",
  "incidencia_ira": {
    "anfotericina_deoxicolato_isolada": "25-30%",
    "anfotericina_lipossomal_isolada": "10-15%",
    "combinacao_deoxicolato_amino": "50-80%",
    "combinacao_lipossomal_amino": "20-30%"
  },
  "estrategias_reducao_risco": [
    "Usar formulacao lipossomal de anfotericina",
    "Hidratar com SF 0.9% 500mL antes de cada infusao",
    "Repor potassio e magnesio profilaticamente",
    "Evitar outros nefrotoxicos",
    "Dose unica diaria de aminoglicosideo"
  ],
  "alternativas": {
    "para_anfotericina": ["Voriconazol", "Caspofungina", "Micafungina", "Anidulafungina"],
    "para_aminoglicosideo": ["Fluoroquinolonas", "Cefepime", "Meropenem"]
  },
  "created_at": "2026-02-06",
  "updated_at": "2026-02-06",
  "version": "1.0"
}
